Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HB 2198

Next Previous
Drug Profile

HB 2198

Alternative Names: HB-2198

Latest Information Update: 17 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hinge Bio
  • Class Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies
  • Mechanism of Action B cell inhibitors; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 23 Mar 2026 Phase-I clinical trials in Systemic lupus erythematosus (Treatment-experienced) in Australia (IV) (NCT07491900)
  • 19 Mar 2026 Hinge Bio initiates a phase I trial (In volunteers) in Australia (IV, Infusion) (NCT07439263)
  • 23 Feb 2026 Hinge Bio plans a phase I trial (In volunteers) (IV, Infusion) In February 2026 (NCT07439263)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top